What are the precautions for taking ixazomib?

Ixazomib is a monoclonal antibody used with other drugs to treat multiple myeloma in people who have already received one other therapy. Ixazomibis a second-generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in 2015 11 months. Ixazomib citrate marketed by Takeda Pharmaceuticals under the trade nameNinlaro is a prodrug that is rapidly converted to its active metabolite ixazomib upon administration.

What are the precautions for taking Ixazomib(Ixazomib)?

1.Thrombocytopenia. Thrombocytopenia has been reported in ixazomib patients, with platelet nadir typically occurring on days 14-21 of each 28-day cycle and returning to baseline at the beginning of the next cycle. Monitor platelet counts at least monthly duringixazomibtreatment. Consider more frequent monitoring during the first three cycles. Control thrombocytopenia and platelet transfusions with dose adjustments.

2.Gastrointestinal toxicity

Diarrhoea, constipation, nausea, and vomiting have been reported with ixazomib, occasionally requiring the use of antidiarrheal and antiemetics and supportive care. Diarrhea was reported in 52% of patients in the ixazomib regimen and 43% in the placebo regimen, and constipation was reported in 35% of patients in the ixazomib regimen and 28% in the placebo regimen. span>, nausea was 32% and 23%, and vomiting was 26% and 13% respectively. 3%of patients in the ixazomibregimen and 2%of patients in the placebo regimen discontinued one or more of the three drugs due to diarrhea. For 3 level or 4Adjust dose for grade symptoms.

3.Peripheral neuropathy. The most commonly reported reaction is peripheral sensory neuropathy. Peripheral motor neuropathy was uncommon (<1%) in either regimen. 4%of patients in the ixazomibregimen discontinued one or more of the three drugs due to peripheral neuropathy compared with 1%of the patients in the placebo regimen. Patients should be monitored for symptoms of neuropathy. Dosage adjustments may be required in patients who develop new or worsening peripheral neuropathy.

4.Peripheral edema. Grade 3 peripheral edema was reported in 2% and 1% of patients in the ixazomib and placebo regimens, respectively. Peripheral edema resulted in discontinuation of one or more of the three drugs in less than 1% of patients in both regimens. Assess potential causes and provide supportive care if necessary. Adjust the dose of dexamethasone according to the prescribing information or adjust the dose of ixazomib for Grade 3 or Grade 4 symptoms.

5.Skin reaction. Severe adverse reactions of rash were reported in less than1% of patients in the ixazomib regimen. The most common types of rash reported in both regimens included maculopapular and macular rash. In both regimens, rash led to discontinuation of one or more of the three drugs in less than 1% of patients. Control rash with supportive care or dose adjustment (if grade 2 or higher). Ixazomib has been reported to have Stevens-Johnson syndrome, including one death. If Stevens-Johnson syndrome occurs, discontinueixazomiband manage as clinically indicated.

6.Thrombotic microangiopathy. Cases of thrombotic microangiopathy, sometimes fatal, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) have been reported in patients receivingixazomib. Monitor for signs and symptoms of TTP/HUS disease. If the diagnosis is in doubt, discontinueixazomiband undergo evaluation. If the diagnosis of TTP/HUS is ruled out, consider restarting ixazomib. The safety of reinitiating ixazomibtherapy in patients with pre-existing TTP/HUS is unknown.

7.Hepatotoxicity. The incidence of drug-induced liver injury, hepatocellular injury, hepatic steatosis, hepatitis cholestasis and hepatotoxicity has been reported to be less than1% in patients treated with ixazomib. There have been reports of hepatotoxicity (NINLARO 10% and 9% in the placebo regimen). Monitor liver enzymes regularly and adjust dose for Grade 3 or Grade 4 symptoms.

8.Embryo-Fetal Toxicity. Based on its mechanism of action and animal studies, ixazomib can cause harm to the fetus when given to pregnant women. Ixazomibcaused embryo-fetotoxicity in pregnant rats and rabbits, resulting in exposures slightly higher than those observed in patients receiving recommended doses. Inform pregnant women of potential risks to the fetus. Advise females of childbearing potential to use an effective non-hormonal method of contraception duringixazomibtreatment and for90days after the last dose. Advise men with female partners to use effective contraception during treatment with ixazomib and for 90 days after the last dose. The retail price of Lucius Pharmaceuticals in Laos4mg*3 tablets is around 900 yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.